SCHEMBL26523757

SCHEMBL26523757

CC(C)[C@@H]1CNC[C@H](C)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20334898 1.00
SCHEMBL24070639 1.00
SCHEMBL21155326 0.85 CCR5 (0.30)
SCHEMBL21155362 0.85 CCR5 (0.30)
SCHEMBL23773464 0.85 CCR5 (0.30)
SCHEMBL16633716 0.82 GBA1 (0.36)
SCHEMBL463582 0.78
SCHEMBL71767 0.76
SCHEMBL73455 0.76
SCHEMBL579357 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4635494-A2 AMIDO HETEROAROMATIC COMPOUNDS Astrazeneca AB (SE) 2025-10-22 EP disclosed
EP-4514782-B1 AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES ASTRAZENECA AB (SE) 2025-09-10 EP disclosed
US-12291524-B2 Amido heteroaromatic compounds ASTRAZENECA AB (SE) 2025-05-06 US disclosed
EP-4514782-A1 AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES Astrazeneca AB (SE) 2025-03-05 EP disclosed
US-20250011311-A1 AMIDO HETEROAROMATIC COMPOUNDS ASTRAZENECA AB (SE) 2025-01-09 US disclosed
CN-119173506-A Amide heteroaromatic compounds for the treatment of liver diseases 阿斯利康(瑞典)有限公司 2024-12-20 CN disclosed
WO-2023225302-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2023-11-23 WO disclosed
US-20230373983-A1 AMIDO HETEROAROMATIC COMPOUNDS ASTRAZENECA AB (SE) 2023-11-23 US disclosed
WO-2023222850-A1 AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES ASTRAZENECA AB (SE) 2023-11-23 WO disclosed
WO-2023183520-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER A2A PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed